Adriana Cervo

Scopus Publications

Risk of Developing Low-Level Viral Rebound Among People With HIV Receiving 2- or 3-Drug Regimens: A Case-Control Study Nested in the ICONA Cohort
Alessandra Vergori, Adriana Cervo, Ashley Roen, Roberta Gagliardini, Tommaso Clemente, Valentina Mazzotta, Eugenia Quiros-Roldan, Franco Maggiolo, Sergio Lo Caputo, Cristina Mussini, Andrea Antinori, Alessandro Cozzi-Lepri, ICONA Foundation Study, A d'Arminio Monforte, A Antinori, S Antinori, A Castagna, M Cernuschi, L Cosmaro, A Di Biagio, E Dibrino, E Girardi, S Lo Caputo, G C Marchetti, C Mussini, E Quiros-Roldan, L Sarmati, B Suligoi, C Torti, A d’Arminio Monforte, A Antinori, A Castagna, F Ceccherini-Silberstein, A Cingolani, A Cozzi-Lepri, A Di Biagio, R Gagliardini, A Giacomelli, E Girardi, A Gori, S Lo Caputo, G Marchetti, F Maggiolo, C Mussini, M Puoti, C F Perno, A Tavelli, A Antinori, A Bandera, S Bonora, A Calcagno, A Castagna, F Ceccherini-Silberstein, A Cervo, A Cingolani, P Cinque, A Cozzi-Lepri, A d’Arminio Monforte, A De Vito, A Di Biagio, A Fortunato, R Gagliardini, A M Geretti, A Giacomelli, E Girardi, N Gianotti, A Gori, G Guaraldi, S Lanini, G Lapadula, M Lichtner, A Lai, S Lo Caputo, G Madeddu, F Maggiolo, V Malagnino, I Mastrorosa, G Marchetti, A Mondi, V Mazzotta, C Muccini, C Mussini, S Nozza, C F Perno, S Piconi, C Pinnetti, M C Poliseno, M Puoti, E Quiros Roldan, R Rossotti, S Rusconi, M M Santoro, A Saracino, L Sarmati, V Spagnuolo, N Squillace, V Svicher, L Taramasso, C Tincati, C Torti, A Vergori, A Cozzi-Lepri, S De Benedittis, I Fanti, M Giotta, S Lanini, N Lentini, M Muccio, R Pastorino, A Rodano’, A Roen, A Tavelli, S Bazzichetto, M Cernuschi, L Cosmaro, A Perziano, V Calvino, D Russo, M Farinella, N Policek, V L Del Negro, S Carrara, S Graziano, G Prota, H Sadeghi, V Sala, S Truffa, D Vincenti, R Rovito, A Giacometti, A Costantini, V Barocci, A Saracino, C Santoro, E Milano, L Comi, D Valenti, P Viale, A Zupparoli, S Cretella, E M Erne, A Pieri, E Quiros Roldan, E Focà, S Minniti, B Menzaghi, C Abeli, L Chessa, F Pes, C Sagnelli, L Alessio, G Nunnari, B M Celesia, J Vecchiet, K Falasca, A Pan, S Dal Zoppo, D Segala, A Bartoloni, B Borchi, C Costa, A Castellaccio, S Lo Caputo, A Narducci, M Bassetti, E Pontali, S Blanchi, N Bobbio, C Del Borgo, R Marocco, G Mancarella, S Piconi, C Molteni, S Rusconi, G Canavesi, P Colletti, G Pellicanò, Y Russotto, G Marchetti, S Antinori, A Gori, M Puoti, A Castagna, A Bandera, G Bozzi, M V Cossu, V Iannone, R Lolatto, M C Moioli, G Carrozzo, N Capra, M Augello, D Moschese, C Mussini, M Menozzi, P Bonfanti, G Lapadula, I Gentile, V Esposito, R Viglietti, N Coppola, F M Fusco, G Di Filippo, V Rizzo, N Sangiovanni, S Martini, A M Cattelan, B Bragato, A Cascio, C Iaria, M Trizzino, R Gulminetti, G De Socio, E Schiaroli, G Parruti, F Sozio, D Messeri, S I Bonelli, C Lazzaretti, R Corsini, A Antinori, C Torti, G D’Ettorre, L Sarmati, A Latini, A Cingolani, G Micheli, S Lamonica, M Capozzi, M Camici, I Mezzaroma, M Rivano Capparuccia, G Iaiani, C Stingone, L Gianserra, J Paulicelli, M M Plazzi, L Bortolani, M Fusto, G Madeddu, G Moi, M Fabbiani, F Montagnani, A Franco, R Fontana Del Vecchio, C Ucciferri, C Di Giuli, G C Orofino, G Calleri, G Di Perri, S Bonora, D Meloni, C Tascini, M Cotrufo, G Battagin, S Nicolè, G Starnini, S Dell’Isola
Open Forum Infectious Diseases, 2026
Background The risk of developing low-level viral rebound (LLVR) after achieving human immunodeficiency virus HIV-1 (HIV) RNA suppression with 2-drug regimens (2DR) compared to 3-drug regimens (3DR) remains uncertain. Methods We conducted a matched 1:3 case-control study nested within the ICONA cohort including persons with HIV (PWH) who achieved virological suppression (≥2 consecutive HIV-RNA ≤50 copies/mL over 6 months) after 11 November 2014 (baseline [BL]). Cases were defined as PWH experiencing a single HIV-RNA of 51–199 copies/mL after BL (index date); controls were defined as those who maintained HIV-RNA ≤50 copies/mL up to the index date and were matched for history of care gaps and number of drugs failed. The cumulative incidence of LLVR after virological suppression was estimated using Kaplan–Meier methods, and conditional logistic regression models were used to evaluate the association between the current antiretroviral therapy regimen (2DR [dolutegravir/lamivudine, dolutegravir/rilpivirine, dolutegravir/doravirine, or cabotegravir/rilpivirine] vs 3DR [dolutegravir, bictegravir, rilpivirine, doravirine, boosted darunavir, or boosted atazanavir–based with a backbone of tenofovir and lamivudine or emtricitabine]) and LLVR risk. In sensitivity analyses cases were defined as PWH experiencing 2 consecutive HIV-RNA of 51–199 copies/mL. Results Among 1033 PWH (261 cases, 772 matched controls), 21% were female, median age was 43 (interquartile range [IQR], 34–51) years, and BL CD4 count was 601 (IQR, 379–826) cells/μL; 2DR use was 25% in cases versus 29% in controls (P = .23). Two years after viral suppression, cumulative LLVR incidence was 2.7% (95% CI, 2.3%–3.1%) when considering single LLVR events and 1.8% (95% CI, 1.4%–2.1%) when limited to 2 consecutive values. After adjusting for confounding, evidence for an association with current regimen was inconclusive (adjusted odds ratio, 0.86 [95% CI, .57–1.29]). Conclusions Despite the wide range of plausibility, we can exclude a risk of LLVR higher than 29% when using 2DR versus 3DR regimens.
‘Leaving no stones unturned’: up to 10 years results on the effectiveness, tolerability and metabolic safety of dolutegravir+lamivudine (DTG+3TC) as a switch regimen in the ODOACRE cohort
Arturo Ciccullo, Gianmaria Baldin, Adriana Cervo, Letizia Oreni, Maria Mazzitelli, Giuseppe Gasparro, Marianna Menozzi, Mario Cesaretti, Francesco Bassani, Filippo Lagi, Francesca Lombardi, Andrea Giacomelli, Alberto Borghetti, Massimiliano Fabbiani, Stefano Rusconi, Annamaria Cattelan, Spinello Antinori, Cristina Mussini, Simona Di Giambenedetto
Journal of Antimicrobial Chemotherapy, 2026
Background Dolutegravir plus lamivudine (DTG+3TC) is widely used as a two-drug switch regimen for virologically suppressed PWH. We report long-term real-world data on effectiveness, tolerability, immunological recovery and metabolic/cardiovascular outcomes in a large, multicentre Italian cohort. Methods We performed a retrospective observational analysis of participants in the ODOACRE cohort who switched to DTG+3TC between January 2015 and January 2025 across eight Italian centres. Inclusion criteria were age ≥18, HIV-RNA <50 copies/mL for ≥6 months at switch, HBsAg negative. Primary outcomes were time to virological failure (VF) and time to treatment discontinuation (TD) for any cause. Kaplan–Meier survival analysis and Cox regression models were used to evaluate predictors. Changes in metabolic and immunological markers were assessed using linear mixed models and linear regression. Results A total of 2535 participants were included. Estimated probabilities of maintaining virological suppression were 99.5% at 48 weeks, 96.1% at 240 weeks and 90.4% at 480 weeks. In multivariate analysis, longer time since HIV diagnosis (per year aHR 1.038) and zenith HIV-RNA >500 000 copies/mL (aHR 2.205) predicted VF, whereas longer prior virological suppression was protective (per year aHR 0.869). During 9721.6 PYFU we observed 362 TDs (3.72 per 100 PYFU), with probabilities of regimen maintenance of 94.4%, 83.5% and 78.7% at weeks 48, 240 and 480, respectively. Conclusions In our real-world cohort with extended follow-up, DTG+3TC as a switch regimen was associated with durable virological suppression and favourable tolerability. Metabolic findings should be considered descriptive and exploratory, within the limits of an observational, uncontrolled study.
Impact of Vancomycin-Resistant Enterococci (VRE)–Active Perioperative Prophylaxis in Liver Transplant Patients Colonized by VRE
Giulia Jole Burastero, Emmanuel Q Wey, Veronica Guidetti, Samuele Cantergiani, Valentina Menozzi, Davide Lo Porto, Andrea Cona, Amreen Khan, Valentina Serra, Giacomo Assirati, Giovanni Guaraldi, Giovanni Dolci, Marianna Meschiari, Adriana Cervo, Martina Tosi, Salvatore Gruttadauria, Joerg-Matthias Pollok, Fabrizio Di Benedetto, Alessandra Mularoni, Cristina Mussini, Erica Franceschini
Clinical Infectious Diseases, 2026
Background Data regarding the effectiveness of vancomycin-resistant Enterococci (VRE)–active prophylaxis for preventing early post–liver transplantation (LT) VRE infections in VRE-colonized patients are scarce. Methods 131 pre-LT VRE-colonized patients who underwent LT were enrolled in a retrospective, observational, multicenter study. The incidence of early-onset VRE infections was compared between patients who received active prophylaxis for VRE and those who did not. Results Sixty-nine (52.7%) and 62 (47.3%) patients were enrolled in the VRE-active and non–VRE-active prophylaxis group. Tigecycline was the most common drug prescribed as VRE-active for prophylaxis (55/69; 79.7%). There was no significant difference in the number of patients who developed early-onset VRE infections in the VRE-active versus non–VRE-active groups at 7 (0 [0.0%] vs 2 [3.2%]; P = .222), 14 (4 [5.7%] vs 4 [6.4%]; P = 1.000), and 30 (6 [8.7%] vs 8 [12.9%]; P = .621) days post-LT, respectively. Risk of early-onset VRE infection within 30 days was not lower in the VRE-active group (log-rank P = .16 with Kaplan-Meier analysis; odds ratio [OR]: .643; 95% CI: .210–1.969; P = .439 with univariate analysis). Conversely, early infections caused by any pathogen were significantly lower in the VRE-active prophylaxis group compared with the control group (11 [15.9%] vs 20 [32.2%]; P = .047). Tigecycline prophylaxis was associated with a lower risk of early-onset infections with multivariate analysis (OR: .106; 95% CI: .015–.745; P = .024) and after adjusting for propensity score (adjusted OR: .146; 95% CI: .031–.708; P = .017). Conclusions VRE-active prophylaxis at LT did not reduce the incidence of early post-LT VRE infections and should not be recommended.
HIV infection among adolescents and young adults in Italy: Epidemiology, viro-immunological and treatment outcomes
Francesco Maria Fusco, Ilaria Mastrorosa, Francesca Vichi, Adriana Cervo, Annalisa Saracino, Leonardo Calza, Eugenia Quiros-Roldan, Maria Elisabetta Teti, Andrea Costantini, Antonella Cingolani, Enrico Girardi, Andrea Antinori, Antonella d’Arminio Monforte, Alessandro Tavelli
International Journal of Infectious Diseases, 2026
OBJECTIVES: No previous study described adolescents and young adults (AYAs) with HIV in Italy. Aims were to investigate the temporal trend of AYAs enrolment in the ICONA cohort over 2014-2023, and to compare their baseline characteristics and antiretroviral therapy (ART) outcomes with adults. METHODS: All subjects enrolled in ICONA, the Italian cohort enrolling HIV-1 positive individuals from ART-naïve, over 2014-2023 were grouped into: AYAs (18-24 years old) and adults (≥25). Study outcomes were: time to first ART start, time to treatment discontinuation (TD) of first-line regimen, cause-specific TD, virologic failure, and loss-to-follow-up (LTFU). RESULTS: Overall, 9519 participants: 653 AYAs (6.9%) and 8,866 adults (93.1%). Excluding the decline recorded in 2020, the percentage of AYAs enrolled showed a similar trend before- and after-COVID. Compared with adults, AYAs had a milder clinical presentation, a better viro-immunological status, a higher mean change of cluster of differentiation 4 count over 24 months and, after adjusting, a higher risk of TD for patient's choice/adherence-related issues and LTFU. CONCLUSIONS: The less advanced clinical presentation and more robust immune recovery of AYAs, might depend upon more recent HIV infection, better thymic function, and lower immune activation. The higher risk of TD due to patient's choice/adherence-related issues and LTFU among AYAs is a major concern and suggests the need to create ad hoc clinical care pathways.
Durability of lenacapavir in viremic heavily treatment-experienced people with HIV: Real-world data from the PRESTIGIO Registry
Tommaso Clemente, Golnaz Torkjazi, Nicolò Capra, Roberta Gagliardini, Anna Maria Cattelan, Riccardo Lolatto, Elisa Fronti, Marta Fiscon, Giuseppe Vittorio De Socio, Giancarlo Orofino, Maria Mercedes Santoro, Vincenzo Spagnuolo, the PRESTIGIO Study Group, Antonella Castagna, Vincenzo Spagnuolo, Daniele Armenia, Stefano Bonora, Leonardo Calza, Anna Maria Cattelan, Giovanni Cenderello, Adriana Cervo, Laura Comi, Antonio Di Biagio, Emanuele Focà, Roberta Gagliardini, Andrea Giacomelli, Filippo Lagi, Giulia Marchetti, Stefano Rusconi, Francesco Saladini, Maria Santoro, Maurizio Zazzi, Andrea Galli, Daniele Armenia, Francesco Saladini, Maria Santoro, Maurizio Zazzi, Elisabetta Carini, Sabrina Bagaglio, Girolamo Piromalli, Riccardo Lolatto, Nicolò Capra, Marcello Tavio, Alessandra Mataloni Paggi, Silvia Magnani, Manuela Colafigli, Ornella Schioppa, Stefania Zanussi, Valentina Da Ros, Silvia Rossetto, Annalisa Saracino, Flavia Balena, Laura Comi, Daniela Valenti, Pierluigi Viale, Leonardo Calza, Federica Malerba, Silvia Cretella, Riccardo Riccardi, Francesco Castelli, Emanuele Focà, Davide Minisci, Barbara Menzaghi, Maddalena Farinazzo, Chiara Abeli, Bruno Cacopardo, Maurizio Celesia, Michele Salvatore Paternò Raddusa, Carmen Giarratana, Paolo Fusco, Vincenzo Olivadese, Simona Mongiardi, Angelo Pan, Chiara Fornabaio, Paola Brambilla, Alessandro Bartoloni, Filippo Lagi, Paola Corsi, Trevisan Sasha, Gasparro Giuseppe, Cecilia Costa, Alessio Bellucci, Elisa Mariabelli, Teresa Santantonio, Sergio Lo Caputo, Sergio Ferrara, Arianna Narducci, Emanuele Pontali, Marcello Feasi, Antonio Sarà, Matteo Bassetti, Antonio Di Biagio, Sabrina Blanchi, Stefania Piconi, Martina Bottanelli, Silvia Pontiggia, Valsecchi Giada, Stefano Rusconi, Cinzia Roberta Bassoli, Francesco Bassani, Liana Bevilacqua, Antonella Castagna, Vincenzo Spagnuolo, Camilla Muccini, Tommaso Clemente, Rebecka Papaioannu Borjesson, Riccardo Lolatto, Nicolò Capra, Elisabetta Carini, Sabrina Bagaglio, Girolamo Piromalli, Andrea Galli, Golnaz Torkjazi, Spinello Antinori, Andrea Giacomelli, Tiziana Formenti, Giulia Marchetti, Lidia Gazzola, Fabiana Trionfo Fineo, Massimo Puoti, Cristina Moioli, Federico D’Amico, Simoncini Elena, Sassi Serena, Cristina Mussini, Adriana Cervo, Giulia Nardini, Elio Manzillo, Antonella Gallicchio, Anna Maria Cattelan, Maria Mazzitelli, Antonio Cascio, Marcello Trizzino, Elisa Fronti, Diletta Laccabue, Federica Carli, Roberto Gulminetti, Layla Pagnucco, Mattia Demitri, Alessandra Ferrari, Giuseppe Vittorio De Socio, Daniela Francisci, Elisabetta Schiaroli, Elisa Garlassi, Romina Corsini, Roberta Gagliardini, Marisa Fusto, Loredana Sarmati, Vincenzo Malagnino, Tiziana Mulas, Mirko Compagno, Carlo Torti, Simona Di Giambenedetto, Silvia Lamonica, Pierluigi Salvo, Giovanni Cenderello, Rachele Pincino, Davide Laurenda, Giordano Madeddu, Andrea De Vito, Mario Tumbarello, Massimiliano Fabbiani, Francesca Panza, Ilaria Rancan, Giovanni Di Perri, Stefano Bonora, Micol Ferrara, Andrea Calcagno, Silvia Fantino, Giancarlo Orofino, Guido Calleri, Guastavigna Marta, Stefano Nardi, Marta Fiscon
Journal of Antimicrobial Chemotherapy, 2026
Lenacapavir, the first-in-class capsid inhibitor, targets multiple stages of the HIV lifecycle, thereby inhibiting viral replication.1 Thanks to its new mechanism of action, lenacapavir is approved for use in people with HIV (PWH) who have limited treatment options.2,3 While its efficacy has been demonstrated in clinical trials,4–6 real-world data in PWH with extensive treatment experience remain scarce. We aimed to evaluate the durability and viro-immunological outcomes of lenacapavir-containing regimens in viremic PWH harbouring four-class drug-resistant (4DR) strains
All-Cause Mortality in People with Four-Class Drug-Resistant HIV: A Matched Cohort Analysis with Data from the PRESTIGIO Registry
Andrea Giacomelli, Nicolò Capra, Riccardo Lolatto, Roberta Gagliardini, Tommaso Clemente, Leonardo Calza, Carlo Torti, Filippo Lagi, Chiara Fornabaio, Giulia Marchetti, Giancarlo Orofino, Vincenzo Spagnuolo, , Antonella Castagna, Vincenzo Spagnuolo, Daniele Armenia, Stefano Bonora, Leonardo Calza, Anna Maria Cattelan, Giovanni Cenderello, Adriana Cervo, Laura Comi, Antonio Di Biagio, Emanuele Focà, Roberta Gagliardini, Andrea Giacomelli, Filippo Lagi, Giulia Marchetti, Stefano Rusconi, Francesco Saladini, Maria Mercedes Santoro, Maurizio Zazzi, Andrea Galli, Daniele Armenia, Francesco Saladini, Maria Mercedes Santoro, Maurizio Zazzi, Elisabetta Carini, Sabrina Bagaglio, Girolamo Piromalli, Riccardo Lolatto, Marcello Tavio, Alessandra Mataloni Paggi, Ornella Schioppa, Valentina Da Ros, Annalisa Saracino, Flavia Balena, Laura Comi, Daniela Valenti, Claudia Suardi, Pierluigi Viale, Leonardo Calza, Federica Malerba, Silvia Cretella, Riccardo Riccardi, Francesco Castelli, Emanuele Focà, Davide Minisci, Francesca Pennati, Barbara Menzaghi, Maddalena Farinazzo, Bruno Cacopardo, Maurizio Celesia, Michele Salvatore Paternò Raddusa, Carmen Giarratana, Paolo Fusco, Vincenzo Olivadese, Angelo Pan, Chiara Fornabaio, Paola Brambilla, Alessandro Bartoloni, Filippo Lagi, Paola Corsi, Seble Tekle Kiros, Filippo Ducci, Susanna Giachè, Cecilia Costa, Alessio Bellucci, Elisa Mirabelli, Teresa Santantonio, Sergio Lo Caputo, Sergio Ferrara, Arianna Narducci, Emanuele Pontali, Marcello Feasi, Antonio Sarà, Matteo Bassetti, Antonio Di Biagio, Sabrina Blanchi, Antonella Castagna, Vincenzo Spagnuolo, Camilla Muccini, Elisabetta Carini, Sabrina Bagaglio, Riccardo Lolatto, Andrea Galli, Rebecka Papaioannu Borjesson, Tommaso Clemente, Girolamo Piromalli, Spinello Antinori, Andrea Giacomelli, Tiziana Formenti, Fabiola Schiavo, Giulia Marchetti, Lidia Gazzola, Fabiana Trionfo Fineo, Massimo Puoti, Cristina Moioli, Federico D’Amico, Cristina Mussini, Adriana Cervo, Elio Manzillo, Amedeo Lanzardo, Anna Maria Cattelan, Maria Mazzitelli, Antonio Cascio, Marcello Trizzino, Elisa Fronti, Diletta Laccabue, Federica Carli, Roberto Gulminetti, Layla Pagnucco, Mattia Demitri, Daniela Francisci, Giuseppe De Socio, Elisabetta Schiaroli, Elisa Garlassi, Romina Corsini, Roberta Gagliardini, Marisa Fusto, Loredana Sarmati, Vincenzo Malagnino, Tiziana Mulas, Mirko Compagno Carlo Torti, Simona Di Giambenedetto, Silvia Lamonica, Pierluigi Francesco Salvo, Giovanni Cenderello, Rachele Pincino, Mario Tumbarello, Massimiliano Fabbiani, Francesca Panza, Ilaria Rancan, Giovanni Di Perri, Stefano Bonora, Micol Ferrara, Andrea Calcagno, Silvia Fantino, Stefano Nardi, Marta Fiscon
Clinical Infectious Diseases, 2025
People with human immunodeficiency virus (HIV) (PWH) with 4-drug class resistance (4DR) had a higher risk of death than non-4DR PWH, primarily due to lower CD4 cell counts. The priority for this vulnerable population is achieving virological control to enable immune recovery.
Evaluation of HIV-1 DNA resistance evolution in highly treatment-experienced and multi-resistant individuals under suppressive antiretroviral therapy: a longitudinal study from the PRESTIGIO Registry
D Armenia, G Marchegiani, V Spagnuolo, M C Bellocchi, L Galli, T Clemente, L Carioti, R Lolatto, M Ferrara, R Gagliardini, G C Marchetti, C Torti, G De Socio, C Fornabaio, M Zazzi, A Castagna, M M Santoro, , Antonella Castagna, Vincenzo Spagnuolo, Daniele Armenia, Stefano Bonora, Leonardo Calza, Anna Maria Cattelan, Giovanni Cenderello, Adriana Cervo, Laura Comi, Antonio Di Biagio, Emanuele Focà, Roberta Gagliardini, Andrea Giacomelli, Filippo Lagi, Giulia Marchetti, Stefano Rusconi, Francesco Saladini, Maria Santoro, Maurizio Zazzi, Andrea Galli, Daniele Armenia, Francesco Saladini, Maria Santoro, Maurizio Zazzi, Elisabetta Carini, Sabrina Bagaglio, Girolamo Piromalli, Riccardo Lolatto, Nicolò Capra, Marcello Tavio, Alessandra Mataloni Paggi, Silvia Magnani, Manuela Colafigli, Ornella Schioppa, Stefania Zanussi, Valentina Da Ros, Silvia Rossetto, Annalisa Saracino, Flavia Balena, Laura Comi, Daniela Valenti, Pierluigi Viale, Leonardo Calza, Federica Malerba, Silvia Cretella, Riccardo Riccardi, Francesco Castelli, Emanuele Focà, Davide Minisci, Barbara Menzaghi, Maddalena Farinazzo, Chiara Abeli, Bruno Cacopardo, Maurizio Celesia, Michele Salvatore Paternò Raddusa, Carmen Giarratana, Paolo Fusco, Vincenzo Olivadese, Simona Mongiardi, Angelo Pan, Chiara Fornabaio, Paola Brambilla, Alessandro Bartoloni, Filippo Lagi, Paola Corsi, Trevisan Sasha, Gasparro Giuseppe, Cecilia Costa, Alessio Bellucci, Elisa Mariabelli, Teresa Santantonio, Sergio Lo Caputo, Sergio Ferrara, Arianna Narducci, Emanuele Pontali, Marcello Feasi, Antonio Sarà, Matteo Bassetti, Antonio Di Biagio, Sabrina Blanchi, Stefania Piconi, Martina Bottanelli, Silvia Pontiggia, Valsecchi Giada, Stefano Rusconi, Cinzia Roberta Bassoli, Francesco Bassani, Liana Bevilacqua, Antonella Castagna, Vincenzo Spagnuolo, Camilla Muccini, Elisabetta Carini, Sabrina Bagaglio, Riccardo Lolatto, Nicolò Capra, Andrea Galli, Rebecka Papaioannu, Tommaso Clemente, Golnaz Torkjazi, Girolamo Piromalli, Spinello Antinori, Andrea Giacomelli, Tiziana Formenti, Giulia Marchetti, Lidia Gazzola, Fabiana Trionfo Fineo, Massimo Puoti, Cristina Moioli, Federico D’Amico, Simoncini Elena, Sassi Serena, Cristina Mussini, Adriana Cervo, Giulia Nardini, Elio Manzillo, Antonella Gallicchio, Anna Maria Cattelan, Maria Mazzitelli, Antonio Cascio, Marcello Trizzino, Elisa Fronti, Diletta Laccabue, Federica Carli, Roberto Gulminetti, Layla Pagnucco, Mattia Demitri, Alessandra Ferrari, Daniela Francisci, Giuseppe De Socio, Elisabetta Schiaroli, Elisa Garlassi, Romina Corsini, Roberta Gagliardini, Marisa Fusto, Loredana Sarmati, Vincenzo Malagnino, Tiziana Mulas, Mirko Compagno Carlo Torti, Simona Di Giambenedetto, Silvia Lamonica, Pierluigi Salvo, Giovanni Cenderello, Rachele Pincino, Davide Laurenda, Giordano Madeddu, Andrea De Vito, Mario Tumbarello, Massimiliano Fabbiani, Francesca Panza, Ilaria Rancan, Giovanni Di Perri, Stefano Bonora, Micol Ferrara, Andrea Calcagno, Silvia Fantino, Giancarlo Orofino, Guido Calleri, Guastavigna Marta, Stefano Nardi, Marta Fiscon
Journal of Antimicrobial Chemotherapy, 2025
Background This study aimed to clarify whether resistance detected in HIV-1 DNA might evolve in virologically suppressed highly treatment-experienced (HTE) individuals with multidrug resistance (MDR). Methods Twenty-three virologically suppressed HTE MDR individuals from the PRESTIGIO Registry with two longitudinal samples available under virological suppression at two different time points (T0−T1) were analysed. HIV-1 DNA levels were quantified using droplet digital PCR, and resistance was assessed through next-generation sequencing (NGS) set at 5%. Mutational load was also evaluated. Results At T0, individuals had been virologically suppressed for a median time of 3 years (IQR 3–5) under a salvage regimen, mostly containing dolutegravir (95.7%) and/or darunavir (69.6%). The median HIV-1 DNA level was 2588 copies/106 CD4+ cells at T0 and remained stable at T1 (2322 copies/106 CD4+ cells; P = 0.831). Individuals with at least ≥3-class resistance in HIV-1 DNA were 20 (87.0%) at T0 and 18 (78.2%) at T1 (P = 0.607). In those receiving NNRTI-sparing treatment (52.2%), the number of NNRTI major resistance mutation (MRM) significantly decreased over time (T0, 2 [1–3]; T1, 0 [0–1]; P = 0.027). No significant temporal differences in the number of PI, NRTI and integrase strand transfer inhibitor (INSTI) MRM were found. Specific MRM, such as M184V, decreased over time, particularly in individuals who were receiving a 3TC-/FTC-sparing salvage regimen or with a T0 mutational load of &lt;1000 copies/106 CD4+ cells. Conclusions Over a year, HIV-1 DNA MRM generally remained unchanged in suppressed HTE MDR people with HIV (PWH) except for a significant decline in M184V and a reduction of NNRTI resistance in the absence of NNRTI pressure.
Proactive antimicrobial stewardship with real-time microbiological alerts improves management of bloodstream infections
Arianna Di Marcello, Antonella Santoro, Vera Todisco, Erica Franceschini, Gabriella Orlando, Stefania Casolari, Adriana Cervo, Marianna Menozzi, Andrea Bedini, Davide Chemello, Mario Sarti, Jacopo Vecchiet, Katia Falasca, Cristina Mussini, Marianna Meschiari
Jac Antimicrobial Resistance, 2025
Introduction This study aims to assess the impact of proactive Infectious Disease Specialist (IDS) interventions, in addition to standard antimicrobial stewardship (AMS) practices, triggered by real-time microbiological alerts, on improving the appropriateness and timeliness of antimicrobial prescriptions in hospitalized patients with bloodstream infections (BSIs). Methods We conducted a prospective, single-center, pre-post interventional study at the University Hospital of Modena, Italy. Adult inpatients with monomicrobial BSIs between June 2022 and March 2023 were included. During the intervention phase (November 2022–March 2023), real-time microbiological alerts were automatically delivered to IDS consultants, who proactively reviewed therapy. Primary outcomes included the time to effective therapy (TTE) and the time to appropriate therapy (TTA). Secondary outcomes encompassed the duration of antimicrobial therapy, 14 and 30-day mortality from BSI, and hospital length of stay. Results A total of 446 BSI episodes were analyzed (211 pre-intervention, 235 post-intervention). Post-intervention, the rate of appropriate therapy significantly increased (97.4% versus 76.2%, P &lt; 0.001), and TTE was significantly shorter (0.63 versus 0.87 days, P = 0.022). No statistically significant reduction in TTA was observed (1.97 versus 2.37 days, P = 0.081). Early IDS intervention (&lt;48 h) was associated with the shortest TTE and TTA. No significant differences were observed in mortality or hospital stay. Kaplan–Meier analysis showed a higher probability of receiving effective and appropriate therapy earlier in the post-intervention phase (log-rank test P = 0.014; 0.072, respectively). Subgroup analysis showed TTE improvements across MDR pathogens. Conclusions A proactive intervention of IDS, based on automatic microbiological alert, in addition to routine AMS activities, is significantly associated with improved prescription appropriateness, reducing TTE.
Persistence of CXCR4-tropic virus in people living with four-class drug-resistant HIV and its clinical impact in the modern antiretroviral era
Rebecka Papaioannu Borjesson, Sara Diotallevi, Riccardo Lolatto, Giovanni Cenderello, Laura Comi, Antonio Cascio, Annalisa Saracino, Tommaso Clemente, Maria Mazzitelli, Sergio Lo Caputo, Daniele Armenia, Maria Mercedes Santoro, Antonella Castagna, Vincenzo Spagnuolo, , Antonella Castagna, Vincenzo Spagnuolo, Daniele Armenia, Stefano Bonora, Leonardo Calza, Anna Maria Cattelan, Giovanni Cenderello, Adriana Cervo, Laura Comi, Antonio Di Biagio, Emanuele Focà, Roberta Gagliardini, Andrea Giacomelli, Filippo Lagi, Giulia Marchetti, Stefano Rusconi, Francesco Saladini, Maria Mercedes Santoro, Maurizio Zazzi, Andrea Galli, Daniele Armenia, Francesco Saladini, Maria Mercedes Santoro, Maurizio Zazzi, Elisabetta Carini, Sabrina Bagaglio, Girolamo Piromalli, Riccardo Lolatto, Marcello Tavio, Alessandra Mataloni Paggi, Ornella Schioppa, Valentina Da Ros, Annalisa Saracino, Flavia Balena, Laura Comi, Daniela Valenti, Claudia Suardi, Pierluigi Viale, Leonardo Calza, Federica Malerba, Silvia Cretella, Riccardo Riccardi, Francesco Castelli, Emanuele Focà, Davide Minisci, Francesca Pennati, Barbara Menzaghi, Maddalena Farinazzo, Bruno Cacopardo, Maurizio Celesia, Michele Salvatore Paternò Raddusa, Carmen Giarratana, Paolo Fusco, Vincenzo Olivadese, Angelo Pan, Chiara Fornabaio, Paola Brambilla, Alessandro Bartoloni, Filippo Lagi, Paola Corsi, Seble Tekle Kiros, Filippo Ducci, Susanna Giachè, Cecilia Costa, Alessio Bellucci, Elisa Mirabelli, Teresa Santantonio, Sergio Lo Caputo, Sergio Ferrara, Arianna Narducci, Emanuele Pontali, Marcello Feasi, Antonio Sarà, Matteo Bassetti, Antonio Di Biagio, Sabrina Blanchi, Antonella Castagna, Vincenzo Spagnuolo, Camilla Muccini, Elisabetta Carini, Sabrina Bagaglio, Riccardo Lolatto, Andrea Galli, Rebecka Papaioannu Borjesson, Tommaso Clemente, Girolamo Piromalli, Spinello Antinori, Andrea Giacomelli, Tiziana Formenti, Fabiola Schiavo, Giulia Marchetti, Lidia Gazzola, Fabiana Trionfo Fineo, Massimo Puoti, Cristina Moioli, Federico D’Amico, Cristina Mussini, Adriana Cervo, Elio Manzillo, Amedeo Lanzardo, Anna Maria Cattelan, Maria Mazzitelli, Antonio Cascio, Marcello Trizzino, Elisa Fronti, Diletta Laccabue, Federica Carli, Roberto Gulminetti, Layla Pagnucco, Mattia Demitri, Daniela Francisci, Giuseppe De Socio, Elisabetta Schiaroli, Elisa Garlassi, Romina Corsini, Roberta Gagliardini, Marisa Fusto, Loredana Sarmati, Vincenzo Malagnino, Tiziana Mulas, Mirko Compagno Carlo Torti, Simona Di Giambenedetto, Silvia Lamonica, Pierluigi Francesco Salvo, Giovanni Cenderello, Rachele Pincino, Mario Tumbarello, Massimiliano Fabbiani, Francesca Panza, Ilaria Rancan, Giovanni Di Perri, Stefano Bonora, Micol Ferrara, Andrea Calcagno, Silvia Fantino, Stefano Nardi, Marta Fiscon
Journal of Antimicrobial Chemotherapy, 2025
Background CXCR4-tropic HIV seems to be associated with more clinical events than CCR5-tropic virus. Objectives This study aims to describe the effect of the persistence of CXCR4-tropic virus on the occurrence of clinical events in people with four-class drug-resistant HIV. Methods This is a retrospective study on people with four-class drug-resistant HIV from the PRESTIGIO Registry, with at least two HIV-tropism determinations during follow-up. Follow-up accrued from the date of the first four-class drug resistance evidence (baseline) until death, loss to follow-up or freezing date (31 December 2023). Univariable Poisson regression was used to estimate and compare incidence rates of clinical events. Predictors of clinical events were assessed by multivariable Poisson regression. Results A total of 144 people with four-class drug-resistant HIV [47 (33%) with persistent CXCR4-tropism, 39 (27%) with persistent CCR5-tropism and 58 (40%) with a tropism switch during follow-up] were included with a median follow-up of 7.80 years (IQR = 5.80–10.6). Overall, 117 (81.3%) 4DR-PLWH experienced at least one clinical event during follow-up [incidence rate = 32.5 (95% CI = 29.3–35.9)]. The persistence of CXCR4-tropic virus was associated with an increased risk of HIV-related events among people living with four-class drug-resistant HIV, even in modern ART era. After adjusting for age, sex at birth and CD4+/CD8+ at baseline, standardized viremia copy-years [adjusted-incidence rate ratio = 1.66 (95% CI = 1.24–2.26), P &lt; 0.001] and persistent CXCR4-tropism [adjusted-incidence rate ratio: 2.01 (95% CI = 1.04–3.91), P = 0.037] were associated with the occurrence of HIV-related events. Conclusions Our findings confirm CXCR4-tropism as a marker of HIV progression also in the four-class drug-resistant population, suggesting the need of further prioritization of viro-immunological control and studies of pathogenic mechanisms in presence of CXCR4-tropic multidrug-resistant viral strains.
Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort
Roberta Gagliardini, Sara De Benedittis, Alessandro Tavelli, Giuseppe Lapadula, Valentina Mazzotta, et al.
Journal of Antimicrobial Chemotherapy, 2025
Background Phase 3 studies have shown long-acting (LA) cabotegravir/rilpivirine to be effective and tolerable as maintenance therapy in people with HIV (PWH). However, real-life data on their effectiveness are limited. Methods All PWH enrolled in the Icona Cohort who started LA cabotegravir/rilpivirine with HIV-RNA < 50 copies/mL were included. Times to treatment discontinuation (TD) and to virological failure (VF50, two consecutive HIV-RNA >50 copies/mL or one >1000 copies/mL followed by ART switch) were estimated by the Kaplan–Meier method. Cox regression models, adjusted for age, sex and mode of HIV transmission and stratified by the centre, were employed. Results Overall, 583 PWH started LA cabotegravir/rilpivirine. Six VF50 were observed, with a 1 year estimated cumulative probability of virological failure of 1.2% (95% CI, 0.5%–3.0%). Resistance-associated mutations for rilpivirine and cabotegravir were detected in 3/4 and 4/4 participants with VF50, respectively, for which the genotypic resistance test was performed. The 1 year cumulative probability of TD was 11.4% (95% CI, 8.6%–14.9%), mainly caused by toxicity/adverse events (73.2%). Multivariable analysis identified heterosexual intercourse and IV drug use as significant risk factors for TD compared with MSM. Conclusions This analysis demonstrated the short-term effectiveness of cabotegravir/rilpivirine in a real-life setting showing minimal incidence of virological failure but a notable probability of discontinuation due to toxicity or adverse events.
Comparison of Patients With or Without COVID-19 and Without Hematological Diseases Treated for Invasive Pulmonary Aspergillosis: A 5-Year Retrospective Cohort Study with Propensity-Based Adjustment
Sara Volpi, Shaniko Kaleci, Erica Franceschini, Samuele Cantergiani, Gabriella Orlando, Adriana Cervo, Andrea Bedini, Stefania Casolari, Sara Esperti, Davide Chemello, Maddalena Albertini, Laura Cancian, Paola Buonadonna, Jacopo Baldi, Roberto Tonelli, Stefano Busani, Lucia Serio, Lucio Brugioni, Antonello Pietrangelo, Gabriele Melegari, Giovanni Pinelli, Claudia Venturelli, Irene Venturelli, Massimo Girardis, Mario Sarti, Cristina Mussini, Marianna Meschiari
Open Forum Infectious Diseases, 2025
Two-fold increased risk of cardiovascular events in people with MDR HIV: a matched cohort analysis with data from the PRESTIGIO registry
Tommaso Clemente, Sara Diotallevi, Davide Minisci, Antonio Di Biagio, Riccardo Lolatto, Letizia Attala, Giovanni Cenderello, Alessia Siribelli, Camilla Muccini, Sergio Lo Caputo, Marcello Tavio, Rebecka Papaioannu Borjesson, Andrea Giacomelli, Antonella Castagna, Vincenzo Spagnuolo, , Antonella Castagna, Vincenzo Spagnuolo, Daniele Armenia, Stefano Bonora, Leonardo Calza, Anna Maria Cattelan, Giovanni Cenderello, Adriana Cervo, Laura Comi, Antonio Di Biagio, Emanuele Focà, Roberta Gagliardini, Andrea Giacomelli, Filippo Lagi, Giulia Marchetti, Stefano Rusconi, Francesco Saladini, Maria Mercedes Santoro, Maurizio Zazzi, Andrea Galli, Daniele Armenia, Francesco Saladini, Maria Mercedes Santoro, Maurizio Zazzi, Elisabetta Carini, Sabrina Bagaglio, Girolamo Piromall, Riccardo Lolatto, Marcello Tavio, Alessandra Mataloni Paggi, Ornella Schioppa, Valentina Da Ros, Annalisa Saracino, Flavia Balena, Laura Comi, Daniela Valenti, Claudia Suardi, Pierluigi Viale, Leonardo Calza, Federica Malerba, Silvia Cretella, Riccardo Riccardi, Francesco Castelli, Emanuele Focà, Davide Minisci, Francesca Pennati, Barbara Menzaghi, Maddalena Farinazzo, Bruno Cacopardo, Maurizio Celesia, Michele Salvatore Paternò Raddusa, Carmen Giarratana, Paolo Fusco, Vincenzo Olivadese, Angelo Pan, Chiara Fornabaio, Paola Brambilla, Alessandro Bartoloni, Filippo Lagi, Paola Corsi, Seble Tekle Kiros, Filippo Ducci, Susanna Giachè, Cecilia Costa, Alessio Bellucci, Elisa Mirabelli, Teresa Santantonio, Sergio Lo Caputo, Sergio Ferrara, Arianna Narducci, Emanuele Pontali, Marcello Feasi, Antonio Sarà, Matteo Bassetti, Antonio Di Biagio, Sabrina Blanchi, Antonella Castagna, Vincenzo Spagnuolo, Camilla Muccini, Elisabetta Carini, Sabrina Bagaglio, Riccardo Lolatto, Andrea Galli, Rebecka Papaioannu Borjesson, Tommaso Clemente, Girolamo Piromalli, Spinello Antinori, Andrea Giacomelli, Tiziana Formenti, Fabiola Schiavo, Giulia Marchetti, Lidia Gazzola, Fabiana Trionfo Fineo, Massimo Puoti, Cristina Moioli, Federico D’Amico, Cristina Mussini, Adriana Cervo, Elio Manzillo, Amedeo Lanzardo, Anna Maria Cattelan, Maria Mazzitelli, Antonio Cascio, Marcello Trizzino, Elisa Fronti, Diletta Laccabue, Federica Carli, Roberto Gulminetti, Layla Pagnucco, Mattia Demitri, Daniela Francisci, Giuseppe De Socio, Elisabetta Schiaroli, Elisa Garlassi, Romina Corsini, Roberta Gagliardini, Marisa Fusto, Loredana Sarmati, Vincenzo Malagnino, Tiziana Mulas, Mirko Compagno Carlo Torti, Simona Di Giambenedetto, Silvia Lamonica, Pierluigi Francesco Salvo, Giovanni Cenderello, Rachele Pincino, Mario Tumbarello, Massimiliano Fabbiani, Francesca Panza, Ilaria Rancan, Giovanni Di Perri, Stefano Bonora, Micol Ferrara, Andrea Calcagno, Silvia Fantino, Stefano Nardi, Marta Fiscon
Journal of Antimicrobial Chemotherapy, 2025
Comparing the long-term effectiveness and safety of dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide fumarate as first-line regimens: A real life multicentre cohort
Arturo Ciccullo, Gianmaria Baldin, Adriana Cervo, Davide Moschese, Filippo Lagi, Maria Vittoria Cossu, Alessandro Grimaldi, Andrea Giacomelli, Stefano Rusconi, Gaetana Sterrantino, Alberto Borghetti, Spinello Antinori, Cristina Mussini, Simona Di Giambenedetto
Journal of Antimicrobial Chemotherapy, 2025
Polypharmacy, anticholinergic burden and drug-drug interaction assessment in people with four-class-resistant HIV: data from the PRESTIGIO registry
Maria Mazzitelli, Domenico Pontillo, Tommaso Clemente, Antonio Di Biagio, Giovanni Cenderello, Stefano Rusconi, Barbara Menzaghi, Chiara Fornabaio, Elisa Garlassi, Maurizio Zazzi, Antonella Castagna, Anna Maria Cattelan, , Antonella Castagna, Vincenzo Spagnuolo, Laura Galli, Franco Maggiolo, Leonardo Calza, Emanuele Focà, Filippo Lagi, Giovanni Cenderello, Antonio Di Biagio, Giulia Marchetti, Stefano Rusconi, Adriana Cervo, Roberta Gagliardini, Stefano Bonora, Anna Maria Cattelan, Maurizio Zazzi, Maria Mercedes Santoro, Maurizio Zazzi, Maria Mercedes Santoro, Andrea Galli, Francesco Saladini, Daniele Armenia, Elisabetta Carini, Sabrina Bagaglio, Laura Galli, Riccardo Lolatto, Sara Diotallevi, Marcello Tavio, Alessandra Mataloni Paggi, Bagno A Ripoli, Francesca Vichi, Alessio Bellucci, Elisa Mirabelli, Annalisa Saracino, Flavia Balena, Franco Maggiolo, Laura Comi, Daniela Valenti, Claudia Suardi, Leonardo Calza, Federica Malerba, Francesco Castelli, Emanuele Focà, Davide Minisci, Francesca Pennati, Anna Celotti, Francesca Brognoli, Barbara Menzaghi, Maddalena Farinazzo, Bruno Cacopardo, Benedetto Maurizio Celesia, Michele Salvatore Paternò Raddusa, Carmen Giarratana, Carlo Torti, Paolo Fusco, Gabriele Bruno, Angelo Pan, Paola Brambilla, Chiara Fornabaio, Alessandro Bartoloni, Susanna Giachè, Paola Corsi, Seble Tekle Kiros, Filippo Lagi, Filippo Ducci, Teresa Santantonio, Sergio Lo Caputo, Sergio Ferrara, Marianna Narducci, Emanuele Pontali, Marcello Feasi, Antonio Sarà, Matteo Bassetti, Antonio Di Biagio, Sabrina Blanchi, Antonella Castagna, Vincenzo Spagnuolo, Elisabetta Carini, Sabrina Bagaglio, Laura Galli, Riccardo Lolatto, Andrea Galli, Tommaso Clemente, Rebecka Papaioannu Borjesson, Sara Diotallevi, Spinello Antinori, Tiziana Formenti, Andrea Giacomelli, Giulia Marchetti, Lidia Gazzola, Federica De Flaviis, Massimo Puoti, Cristina Moioli, Federico D’Amico, Cristina Mussini, Adriana Cervo, Roncaglia Enrica, Nardini Giulia, Barbara Beghetto, Elio Manzillo, Amedeo Lanzardo, Anna Maria Cattelan, Maria Mazzitelli, Antonio Cascio, Marcello Trizzino, Elisa Fronti, Diletta Laccabue, Roberto Gulminetti, Andrea Zuccarini, Daniela Francisci, Elisabetta Schiaroli, Giuseppe De Socio, Elisa Garlassi, Romina Corsini, Roberta Gagliardini, Marisa Fusto, Loredana Sarmati, Vincenzo Malagnino, Silvia Lamonica, Simona Di Giambenedetto, Tiziana Mulas, Giovanni Cenderello, Rachele Pincino, Mario Tumbarello, Massimiliano Fabbiani, Francesca Panza, Ilaria Rancan, Giovanni Di Perri, Stefano Bonora, Micol Ferrara, Silvia Fantino, Marina Malena, Marta Fiscon
Journal of Antimicrobial Chemotherapy, 2024
Use of next-generation sequencing on HIV-1 DNA to assess archived resistance in highly treatment-experienced people with multidrug-resistant HIV under virological control: data from the PRESTIGIO Registry
Daniele Armenia, Vincenzo Spagnuolo, Maria C Bellocchi, Laura Galli, Leonardo Duca, Greta Marchegiani, Tommaso Clemente, Luca Carioti, Riccardo Lolatto, Leonardo Calza, Benedetto M Celesia, Antonio Cascio, Daniela Francisci, Annalisa Saracino, Carlo Torti, Maurizio Zazzi, Antonella Castagna, Maria M Santoro, , Antonella Castagna, Vincenzo Spagnuolo, Laura Galli, Franco Maggiolo, Leonardo Calza, Emanuele Focà, Filippo Lagi, Giovanni Cenderello, Antonio Di Biagio, Giulia Marchetti, Stefano Rusconi, Adriana Cervo, Roberta Gagliardini, Stefano Bonora, Anna Maria Cattelan, Maurizio Zazzi, Maria Mercedes Santoro, Maurizio Zazzi, Maria Mercedes Santoro, Andrea Galli, Francesco Saladini, Daniele Armenia, Elisabetta Carini, Sabrina Bagaglio, Laura Galli, Riccardo Lolatto, Sara Diotallevi, Marcello Tavio, Alessandra Mataloni Paggi, Francesca Vichi, Alessio Bellucci, Elisa Mirabelli, Annalisa Saracino, Flavia Balena, Franco Maggiolo, Laura Comi, Daniela Valenti, Claudia Suardi, Leonardo Calza, Federica Malerba, Francesco Castelli, Emanuele Focà, Davide Minisci, Francesca Pennati, Anna Celotti, Francesca Brognoli, Barbara Menzaghi, Maddalena Farinazzo, Bruno Cacopardo, Benedetto Maurizio Celesia, Michele Salvatore Paternò Raddusa, Carmen Giarratana, Carlo Torti, Paolo Fusco, Gabriele Bruno, Angelo Pan, Paola Brambilla, Chiara Fornabaio, Alessandro Bartoloni, Susanna Giachè, Paola Corsi, Seble Tekle Kiros, Filippo Lagi, Filippo Ducci, Teresa Santantonio, Sergio Lo Caputo, Sergio Ferrara, Marianna Narducci, Emanuele Pontali, Marcello Feasi, Antonio Sarà, Matteo Bassetti, Antonio Di Biagio, Sabrina Blanchi, Antonella Castagna, Vincenzo Spagnuolo, Elisabetta Carini, Sabrina Bagaglio, Laura Galli, Riccardo Lolatto, Andrea Galli, Tommaso Clemente, Rebecka Papaioannu Borjesson, Sara Diotallevi, Spinello Antinori, Tiziana Formenti, Andrea Giacomelli, Giulia Marchetti, Lidia Gazzola, Federica De Flaviis, Massimo Puoti, Cristina Moioli, Federico D’Amico, Cristina Mussini, Adriana Cervo, Roncaglia Enrica, Nardini Giulia, Barbara Beghetto, Elio Manzillo, Amedeo Lanzardo, Anna Maria Cattelan, Maria Mazzitelli, Antonio Cascio, Marcello Trizzino, Elisa Fronti, Diletta Laccabue, Roberto Gulminetti, Andrea Zuccarini, Daniela Francisci, Elisabetta Schiaroli, Giuseppe De Socio, Elisa Garlassi, Romina Corsini, Roberta Gagliardini, Marisa Fusto, Loredana Sarmati, Vincenzo Malagnino, Silvia Lamonica, Simona Di Giambenedetto, Tiziana Mulas, Giovanni Cenderello, Rachele Pincino, Mario Tumbarello, Massimiliano Fabbiani, Francesca Panza, Ilaria Rancan, Giovanni Di Perri, Stefano Bonora, Micol Ferrara, Silvia Fantino, Marina Malena, Marta Fiscon
Journal of Antimicrobial Chemotherapy, 2024
Risk of virological failure after drug burden reduction in people with 4-class drug-resistant HIV on virological suppression: A retrospective cohort analysis of data from the PRESTIGIO Registry
Tommaso Clemente, Sara Diotallevi, Riccardo Lolatto, Roberta Gagliardini, Andrea Giacomelli, Marta Fiscon, Micol Ferrara, Adriana Cervo, Leonardo Calza, Franco Maggiolo, Stefano Rusconi, Maria Mercedes Santoro, Antonella Castagna, Vincenzo Spagnuolo
International Journal of Antimicrobial Agents, 2024
Donor-derived carbapenem-resistant gram-negative bacterial infections in solid organ transplant recipients: Active surveillance enhances recipient safety
Alessandra Mularoni, Andrea Cona, Maria Campanella, Floriana Barbera, Alice Annalisa Medaglia, Adriana Cervo, Nicola Cuscino, Giuseppina Di Mento, Elena Graziano, Jana Dib El Jalbout, Rossella Alduino, Fabio Tuzzolino, Francesco Monaco, Antonio Cascio, Maddalena Peghin, Salvatore Gruttadauria, Alessandro Bertani, Pier Giulio Conaldi, Malgorzata Mikulska, Paolo Antonio Grossi
American Journal of Transplantation, 2024
Impact of COVID-19 pandemic on retention in care of native and migrant people with HIV in the ICONA cohort
Roberta Gagliardini, Andrea Giacomelli, Giorgio Bozzi, Antonella D'Arminio Monforte, Alessandro Tavelli, Valentina Mazzotta, Elena Bruzzesi, Adriana Cervo, Annalisa Saracino, Cristina Mussini, Enrico Girardi, Alessandro Cozzi-Lepri, Andrea Antinori
Travel Medicine and Infectious Disease, 2024
Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitors
Tommaso Clemente, Laura Galli, Riccardo Lolatto, Roberta Gagliardini, Filippo Lagi, Micol Ferrara, Anna Maria Cattelan, Emanuele Focà, Antonio Di Biagio, Adriana Cervo, Leonardo Calza, Franco Maggiolo, Giulia Marchetti, Giovanni Cenderello, Stefano Rusconi, Maurizio Zazzi, Maria Mercedes Santoro, Vincenzo Spagnuolo, Antonella Castagna
BMJ Open, 2024
Vancomycin resistant enterococcus risk factors for hospital colonization in hematological patients: a matched case-control study
Marianna Meschiari, Shaniko Kaleci, Martina Del Monte, Andrea Dessilani, Antonella Santoro, Francesco Scialpi, Erica Franceschini, Gabriella Orlando, Adriana Cervo, Morselli Monica, Fabio Forghieri, Claudia Venturelli, Enrico Ricchizzi, Johanna Chester, Mario Sarti, Giovanni Guaraldi, Mario Luppi, Cristina Mussini
Antimicrobial Resistance and Infection Control, 2023
Long-acting combination of cabotegravir plus rilpivirine: A picture of potential eligible and ineligible HIV-positive individuals from the Italian ARCA cohort
Adriana Cervo, Antonio Russo, Domenico Di Carlo, Andrea De Vito, Lavinia Fabeni, Stefano D'Anna, Leonardo Duca, Agnese Colpani, Marco Fois, Beatrice Zauli, Giulia Mancarella, Anna Carraro, Antonia Bezenchek, Alessandro Cozzi-Lepri, Maria Mercedes Santoro
Journal of Global Antimicrobial Resistance, 2023
Epidemiology and Prevention of Early Infections by Multi-Drug-Resistant Organisms in Adults Undergoing Liver Transplant: A Narrative Review
Giovanni Dolci, Giulia Jole Burastero, Francesca Paglia, Adriana Cervo, Marianna Meschiari, Giovanni Guaraldi, Johanna Chester, Cristina Mussini, Erica Franceschini
Microorganisms, 2023
Efficacy of bezlotoxumab in preventing the recurrence of Clostridioides difficile infection: an Italian multicenter cohort study
Marianna Meschiari, Alessandro Cozzi-Lepri, Adriana Cervo, Guido Granata, Carlotta Rogati, Erica Franceschini, Stefania Casolari, Paola Tatarelli, Daniele Roberto Giacobbe, Matteo Bassetti, Simone Mornese Pinna, Francesco Giuseppe De Rosa, Francesco Barchiesi, Benedetta Canovari, Carolina Lorusso, Giuseppe Russo, Giovanni Cenderello, Antonio Cascio, Nicola Petrosillo, Cristina Mussini
International Journal of Infectious Diseases, 2023
Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
Franco Maggiolo, Roberto Gulminetti, Layla Pagnucco, Margherita Digaetano, Adriana Cervo, Daniela Valenti, Annapaola Callegaro, Cristina Mussini
BMC Infectious Diseases, 2022
“Dangerous liaisons: NAFLD and liver fibrosis increase cardiovascular risk in HIV”
Adriana Cervo, Giada Sebastiani, Jovana Milic, Thomas Krahn, Sergio Mazzola, Salvatore Petta, Antonio Cascio, Giovanni Guaraldi, Giovanni Mazzola
HIV Medicine, 2022
Ceftazidime/Avibactam in Ventilator-Associated Pneumonia Due to Difficult-to-Treat Non-Fermenter Gram-Negative Bacteria in COVID-19 Patients: A Case Series and Review of the Literature
Giulia Jole Burastero, Gabriella Orlando, Antonella Santoro, Marianna Menozzi, Erica Franceschini, Andrea Bedini, Adriana Cervo, Matteo Faltoni, Erica Bacca, Emanuela Biagioni, Irene Coloretti, Gabriele Melegari, Jessica Maccieri, Stefano Busani, Elisabetta Bertellini, Massimo Girardis, Giulia Ferrarini, Laura Rofrano, Mario Sarti, Cristina Mussini, Marianna Meschiari
Antibiotics, 2022
Long-Term Impact of the COVID-19 Pandemic on In-Hospital Antibiotic Consumption and Antibiotic Resistance: A Time Series Analysis (2015–2021)
Marianna Meschiari, Lorenzo Onorato, Erica Bacca, Gabriella Orlando, Marianna Menozzi, Erica Franceschini, Andrea Bedini, Adriana Cervo, Antonella Santoro, Mario Sarti, Claudia Venturelli, Emanuela Biagioni, Irene Coloretti, Stefano Busani, Massimo Girardis, José-María Lòpez-Lozano, Cristina Mussini
Antibiotics, 2022
Two-Tier Care Pathways for Liver Fibrosis Associated to Non-Alcoholic Fatty Liver Disease in HIV Mono-Infected Patients
Giada Sebastiani, Jovana Milic, Adriana Cervo, Sahar Saeed, Thomas Krahn, Dana Kablawi, Al Shaima Al Hinai, Bertrand Lebouché, Philip Wong, Marc Deschenes, Claudia Gioè, Antonio Cascio, Giovanni Mazzola, Giovanni Guaraldi
Journal of Personalized Medicine, 2022
Combination of aztreonam, ceftazidime–avibactam and amikacin in the treatment of VIM-1 Pseudomonas aeruginosa ST235 osteomyelitis
Alessandra Mularoni, Maria Lina Mezzatesta, Michele Pilato, Alice Annalisa Medaglia, Adriana Cervo, Dafne Bongiorno, Ausilia Aprile, Angelo Luca, Stefania Stefani, Paolo Grossi
International Journal of Infectious Diseases, 2021
NASH in HIV
Adriana Cervo, Mohamed Shengir, Keyur Patel, Giada Sebastiani
Current HIV AIDS Reports, 2020
Prediction of esophageal varices by liver stiffness and platelets in persons with human immunodeficiency virus infection and compensated advanced chronic liver disease
Nicolás Merchante, Chiara Saroli Palumbo, Giovanni Mazzola, Juan A Pineda, Francisco Téllez, Antonio Rivero-Juárez, Maria José Ríos-Villegas, James B Maurice, Rachel H Westbrook, Rebekah Judge, Giovanni Guaraldi, Filippo Schepis, Hugo Perazzo, Juergen Rockstroh, Christoph Boesecke, Marina B Klein, Adriana Cervo, Peter Ghali, Philip Wong, Salvatore Petta, Victor De Ledinghen, Juan Macías, Giada Sebastiani
Clinical Infectious Diseases, 2020
Prevalence, predictors, and severity of lean nonalcoholic fatty liver disease in patients living with human immunodeficiency virus
Adriana Cervo, Jovana Milic, Giovanni Mazzola, Filippo Schepis, Salvatore Petta, Thomas Krahn, Bertrand Lebouche, Marc Deschenes, Antonio Cascio, Giovanni Guaraldi, Giada Sebastiani
Clinical Infectious Diseases, 2020
Application of guidelines for the management of nonalcoholic fatty liver disease in three prospective cohorts of HIV-monoinfected patients
G Sebastiani, S Cocciolillo, G Mazzola, A Malagoli, J Falutz, A Cervo, S Petta, T Pembroke, P Ghali, G Besutti, I Franconi, J Milic, A Cascio, G Guaraldi
HIV Medicine, 2020
Suboptimal performance of APRI and FIB-4 in ruling out significant fibrosis and confirming cirrhosis in HIV/HCV co-infected and HCV mono-infected patients
Giovanni Mazzola, Lucia Adamoli, Vincenza Calvaruso, Fabio Salvatore Macaluso, Pietro Colletti, Sergio Mazzola, Adriana Cervo, Marcello Trizzino, Francesco Di Lorenzo, Chiara Iaria, Tullio Prestileo, Ambrogio Orlando, Vito Di Marco, Antonio Cascio
Infection, 2019
Direct-acting antivirals and visceral leishmaniasis: A case report
Claudia Colomba, Laura Saporito, Paola Di Carlo, Manlio Tolomeo, Adriana Cervo, Alberto Firenze, Marcello Trizzino, Antonio Cascio
BMC Infectious Diseases, 2019
Leishmaniasis and biologic therapies for rheumatologic diseases: A concise review
Chiara Iaria, Francesco Scarlata, Valentina Caputo, Teresa Rea, Nicola Serra, Adriana Cervo, Davide Mililli, Annamaria De Luca, Benedetta Romanin, Claudia Colomba
Gazzetta Medica Italiana Archivio Per Le Scienze Mediche, 2018
Madura foot: An imported case of a non-common diagnosis
Infezioni in Medicina, 2018